Key Takeaways
- • PRFX trading at $1.40–$1.42 as of late May 2026, down 85.64% over the 52-week period, reflecting significant shareholder value destruction relative to S&P 500 gains of 27.20%.
- • Severely negative profitability metrics: operating margin of –16,200%, net income of –$4.84M (trailing twelve months), and diluted EPS of –$7.47, indicating the company is unprofitable with substantial losses.
- • Minimal revenue base of $17k (trailing twelve months) with a price-to-sales ratio of 51.46x, suggesting the stock is priced speculatively with limited operational scale or cash generation.
- • Market capitalization of $1.17M with negative enterprise value (–$2.95M), negative operating cash flow of –$3.96M, and levered free cash flow of –$2M, indicating cash burn and financial distress.
- • Positive cash position of $4.14M ($4.90 per share) provides near-term runway, though the company's negative cash flow trajectory and operating losses suggest runway is constrained; patent application announcements have driven 14.58% rallies, though gains have not been sustained.
Summary
PRF Technologies Ltd. (NASDAQ: PRFX) presents a distressed financial profile characteristic of a pre-revenue or cash-burning development-stage enterprise. As of late May 2026, the stock trades in the $1.40 range, having declined 85.64% over the preceding 52 weeks—a performance substantially worse than the broader market's 27.20% gain. The 52-week trading range spans $1.28 to $17.95, indicating extreme volatility and significant capital destruction from peak valuations.
The company's financial statement reveals acute operational challenges. Trailing twelve-month revenue totals only $17,000, generating a negative gross profit of –$53,000 and an EBITDA loss of –$4.35 million. Net income available to common shareholders stands at –$4.84 million, translating to diluted EPS of –$7.47. The operating margin of –16,200% underscores the severity of the loss position relative to the minimal revenue base. Return on assets and return on equity are deeply negative at –38.75% and –90.37%, respectively, indicating the company is destroying shareholder capital and asset value at an accelerating rate.
From a valuation perspective, PRFX exhibits extreme metrics typical of distressed or speculative securities. The trailing price-to-earnings ratio of 0.02 is artificially compressed due to near-zero earnings; the price-to-book ratio of 0.14 suggests the stock trades well below book value of $10.28 per share, potentially indicating market skepticism of asset quality or recovery prospects. The price-to-sales multiple of 51.46x reflects the inverse relationship between minimal revenue and current market capitalization of $1.17 million.
On the balance sheet, total cash of $4.14 million (or $4.90 per share) provides some cushion, though operating cash flow of –$3.96 million and levered free cash flow of –$2 million indicate ongoing cash burn. Total debt remains modest at $21,000, yielding a debt-to-equity ratio of 0.23%, but the company's inability to generate positive cash flow from operations represents the binding constraint. The current ratio of 1.78 suggests adequate short-term liquidity, but deterioration is likely if operating losses persist.
Recent equity announcements citing "innovative patent applications" and "strategic partnerships" have triggered rally spikes—notably a 14.58% gain—suggesting investor appetite for turnaround narratives. However, these rallies lack staying power, and equity market pricing reflects deep skepticism regarding near-term paths to profitability or revenue acceleration. For institutional investors evaluating PRFX as a distressed recovery or statistical arbitrage opportunity, the fundamental risk remains operational: the company must demonstrate material revenue growth and a credible path to cash flow positive status before equity valuation stabilizes.
The company's financial statement reveals acute operational challenges. Trailing twelve-month revenue totals only $17,000, generating a negative gross profit of –$53,000 and an EBITDA loss of –$4.35 million. Net income available to common shareholders stands at –$4.84 million, translating to diluted EPS of –$7.47. The operating margin of –16,200% underscores the severity of the loss position relative to the minimal revenue base. Return on assets and return on equity are deeply negative at –38.75% and –90.37%, respectively, indicating the company is destroying shareholder capital and asset value at an accelerating rate.
From a valuation perspective, PRFX exhibits extreme metrics typical of distressed or speculative securities. The trailing price-to-earnings ratio of 0.02 is artificially compressed due to near-zero earnings; the price-to-book ratio of 0.14 suggests the stock trades well below book value of $10.28 per share, potentially indicating market skepticism of asset quality or recovery prospects. The price-to-sales multiple of 51.46x reflects the inverse relationship between minimal revenue and current market capitalization of $1.17 million.
On the balance sheet, total cash of $4.14 million (or $4.90 per share) provides some cushion, though operating cash flow of –$3.96 million and levered free cash flow of –$2 million indicate ongoing cash burn. Total debt remains modest at $21,000, yielding a debt-to-equity ratio of 0.23%, but the company's inability to generate positive cash flow from operations represents the binding constraint. The current ratio of 1.78 suggests adequate short-term liquidity, but deterioration is likely if operating losses persist.
Recent equity announcements citing "innovative patent applications" and "strategic partnerships" have triggered rally spikes—notably a 14.58% gain—suggesting investor appetite for turnaround narratives. However, these rallies lack staying power, and equity market pricing reflects deep skepticism regarding near-term paths to profitability or revenue acceleration. For institutional investors evaluating PRFX as a distressed recovery or statistical arbitrage opportunity, the fundamental risk remains operational: the company must demonstrate material revenue growth and a credible path to cash flow positive status before equity valuation stabilizes.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.